The alteration of caveolin-1 (Cav-1) during carcinogenesis is of great interest and its over-expression in the tumor cell cytoplasm can predict a poor prognosis of renal cell carcinoma (RCC). However, whether the over-expression in RCC is associated with inherited polymorphism is not clear. In this hospital-based case-control study, the association of Cav-1 genotypes with RCC risk in a central Taiwanese population was investigated. Ninety-two patients with RCC and five hundred and eighty of age/gender-matched healthy controls were recruited and genotyped for six polymorphic sites at Cav-1, C521A (rs1997623), G14713A (rs3807987), G21985A (rs12672038), T28608A (rs3757733), T29107A (rs7804372), and G32124A (rs3807992). The results showed that there were statistically different distributions of the genotypic (P = 0.0170 and 0.0011) and allelic (P = 0.0033 and 0.0352) frequencies for the Cav-1 G14713A and T29107A polymorphisms among RCC patients and control subjects, respectively. As for the haplotype analysis, subjects carrying "GG/AT or GG/AA" at Cav-1 G14713A/T29107A showed a 2.06-fold increased odds ratio of RCC compared to those with GG/TT, while those of any other combinations were of unaltered odds ratios. In conclusion, this is the first report providing evidence showing that Cav-1 genotype is associated with RCC. The results showed that the G allele of the Cav-1 G14713A and the A allele of the Cav-1 T29107A are risky genetic factors for RCC susceptibility and the combinative GG/AT or GG/AA haplotype at Cav-1 G14713A/T29107A can serve as one of the RCC predictors for Taiwanese.
Introduction
Renal cell carcinoma (RCC) is the predominant form of tumor of the kidney (> 80%), and accounts for about 3% of all human malignancies (9, 13) . A significant increase in its incidence has been observed during the last decades, and the RCC annual mortality-to-incidence ratio is on the top among genito-urinary tract tumors (18) . Recently, epidemiologic studies suggested that cigarette smoking, hypertension, obesity, occupational exposures, diet, and family history of cancer are associated with RCC susceptibility (12, 13, 17) , and the genetic susceptibility involved in the etiology of RCC was largely unknown and of great interested for scientists in cancer genomics.
Early from this century, researchers have got interested in caveolae to define how these lipid domains involved in the etiology of various types of human cancer (4) . Caveolin-1 (Cav-1), caveolin-2 and caveolin-3 are the major structural proteins of caveolae and Cav-1 is most abundant and principal structural protein (6, 10) . From the viewpoint of proteomics, the alterations in the expression of Cav-1 in carcinogenesis varied considerably among different types of cancer. For instance, it has been demonstrated that Cav-1 is down-regulated in sarcoma, lung carcinoma, and ovarian carcinoma (3, 21, 22) . However, elevated expression of Cav-1 has been associated with the metastasis of esophageal squamous cell carcinoma and prostate cancer and negatively correlated with patient survival (11, 24) . As for RCC, Steffens and his colleagues reported that over expression of Cav-1 in the tumor cell cytoplasm can serve as a predictor for the poor prognosis of RCC patients (19) . Although the alterations depended much on the tumor site, there is no denying that Cav-1 played an important role in carcinogenesis.
The proteomic evidence for the involvement of Cav-1 in RCC encouraged scientists to conduct further investigations to enlighten the role and its function as diagnostic and prognostic markers in serum and/ or urine of RCC. Above this, it is more valuable to study whether different genotypes of Cav-1 gene are associated with RCC susceptibility to provide predictors at the DNA level for early prediction and prevention. Thus, the aims of this study were to determine the genotypic frequency of six polymorphisms of the Cav-1 gene at C521A (rs1997623), G14713A (rs3807987), G21985A (rs12672038), T28608A (rs3757733), T29107A (rs7804372), and G32124A (rs3807992), and their associations with RCC susceptibility in Taiwan. To the best of our knowledge, this is the first study evaluating the contribution of Cav-1 genotypes to RCC oncology all over the world.
Materials and Methods

Study Population and Sample Collection
The hospital-based study consisted of 92 RCC patients and 580 age-and gender-matched cancerfree controls selected from the Health Examination Cohort of the hospital. The patients, diagnosed with RCC, were recruited at the outpatient clinics of general surgery at the China Medical University Hospital in central Taiwan. The clinical characteristics of the patients including their histological details were all graded and defined by expert surgeons (Dr. Wu's team). All the age-and gender-matched cancer-free controls were genetically unrelated to the RCC patients and had no individual history of cancer. The exclusion criteria of the control group included previous malignancy, metastasized cancer from other or unknown origin and any familial or genetic diseases, and those whose genotypes could not be identified in our system. Extra exclusion criteria of the controls were that if they had symptoms suggestive of RCC, such as hematuria. The study was approved by the Institutional Review Board of the China Medical University Hospital and written-informed consent was obtained from all the participants.
Genotyping Design and Conditions
Each participant donated 3-5 ml venous blood and their genomic DNA was prepared within 2 days from their peripheral blood leucocytes using a QIAamp Blood Mini Kit (Blossom, Taipei, Taiwan) and further processed according to our regular methodology in Cav-1 genotyping (1, 2, 8, 11, 14, 20, 23, 25) . Briefly, the following primers were used: for Cav-1 C521A (rs1997623), 5'-GTGTCCGCTTCTGC TATCTG-3' and 5'-GCCAAGATGCAGAAGGAG TT-3'; for Cav-1 G14713A (rs3807987), 5'-CCTTCCAG-TAAGCAAGCTGT-3' and 5'-CCTCTCAATCTT-GCCATAGT-3'; for Cav-1 G21985A (rs12672038), 5'-GGTGTCAGCAAGGCTATGCT-3' and 5'-CCA-GACACTCAGAATGTGAC-3'; for Cav-1 T28608A (rs3757733), 5'-GCTCAACCTCATCTGAGGCA-3' and 5'-GGCCTATTGTTGAGTGGATG-3'; for Cav-1 T29107A (rs7804372), 5'-GCCTGAATTG-CAATCCTGTG-3' and 5'-ACGGTGTGAACACG-GACATT-3'; and for Cav-1 G32124A (rs3807992),
The following uniform cycling conditions were performed: one cycle at 94°C for 5 min; 35 cycles of 94°C for 30 s, 55°C for 30 s, and 72°C for 30 s; and a final extension at 72°C for 10 min. The PCR products were subject to 3% gel electrophoresis after the digestion of Avr II, Bfa I, Hae III, Tsp509 I, Sau3AI and Nla III, restriction enzymes for Cav-1 C521A (cut from 485 bp C type into 170+315 bp T type), Cav-1 G14713A (cut from 268 bp A type into 66+202 bp G type), Cav-1 G21985A (cut from 251+43 bp A type into 153+98+43 bp G type), Cav-1 T28608A (cut from 298 bp T type into 100+198 bp A type), Cav-1 T29107A (cut from 336 bp A type into 172+164 bp T type), and Cav-1 G32124A (cut from 213+142+67 bp A type into 142+118+95+67 bp T type), respectively.
Statistical Analyses
To ensure that the controls used were representative of the general population and to exclude the possibility of genotyping error, the deviation of the genotype frequencies of Cav-1 single nucleotide polymorphisms (SNP) in the control subjects from those expected under the Hardy-Weinberg equilibrium was assessed using the goodness-of-fit test. Pearson's Chi-square test or Fisher's exact test (when the expected number in any cell was less than five) was used to compare the distribution of the Cav-1 genotypes between cases and controls. Cancer risk associated with the genotypes was estimated as odds ratio (ORs) and 95% confidence intervals (CIs) using unconditional logistic regression. The data was recognized as significant when the statistical P-value was less than 0.05. All statistical tests were performed using SAS, Version 9.1.3 (SAS Institute Inc., Cary, NC, USA) on two sided probabilities.
Results
Frequency distributions of baseline clinical characteristics among renal cell carcinoma patients and healthy controls are presented in Table 1 . Since we have matched the patients and healthy controls in age, gender and personal behaviors, there is no difference in the frequency distributions of these clinical characteristics (P > 0.05) ( Table 1) . Noticeably, hypertension seems to be a risky factor for RCC (P = 0.0130) ( Table 1) .
In Table 2 , the frequency distributions of the genotypes for the Cav-1 C521A, G14713A, G21985A, T28608A, T29107A and G32124A of all the subjects are presented. Among them, the genotypic distributions of Cav-1 G14713A and T29107A were significantly different between RCC and control groups (P = 0.0170 and 0.0011, respectively) ( Table 2) . As for Cav-1 C521A, G21985A, T28608A and G32124A, the distributions were not different between the two groups (all P > 0.05) ( Table 2) . Overall, the genotypes of two SNPs on Cav-1, G14713A and T29107A, are associated with RCC risk and may be biomarkers for Taiwan RCC early detection and prediction. The typical polymerase chain reaction-restriction fragment length polymorphism analysis for the genotypes of two significant SNPs (Cav-1 G14713A and T29107A) were shown in Fig. 1 .
The distributions of allelic frequencies for the Cav-1 C521A, G14713A, G21985A, T28608A, T29107A and G32124A among RCC patients and controls are shown in Table 3 . The two Cav-1 SNPs found to be significantly associated with RCC risk in Table 2 , G14713A and T29107A, were also found to be associated with higher RCC in their allelic frequency analysis (P = 0.0033 and 0.0352, respectively) ( Table  3) . As for the other four SNPs, the distributions of their allelic frequencies were not significantly different between the control and RCC patient groups (all P > 0.05) ( Table 3) .
The two significant SNPs of Cav-1 gene, Cav-1 G14713A and T29107A, were further analyzed by haplotype distribution analysis to evaluate their combinative contribution to RCC susceptibility (Table 4) . Compared with the wild-type GG/TT haplotype of Cav-1 G14713A/T29107A, the GG/AT or GG/AA group has a higher risk of RCC (OR = 2.06, 95% CI = 1.19-3.55). Other combinations of AG/TT, AG/AT or AG/AA, and AA/TT, AA/AT or AA/AA conferred nonsignificant 0.75-fold (95% CI = 0.31-1.83), 1.57-fold (95% CI = 0.77-3.19) and 0.16-fold (95% CI = 0.02-1.19) effect on RCC risk compared to the wild-type GG/TT haplotype, respectively (Table 4) . After adjusted with individual age, gender and behaviors, the trends and significances still unaltered.
Discussion
To our knowledge, this is the first paper to identify and validate the association between the RCC risk and Cav-1 genotype. In 2010, Moore and his colleagues found that among kidney transplant donors, AA genotype of Cav-1 tagged SNP rs4730751, was significantly associated with allograft failure (16) . The knockdown aberration of Cav-1 expression level has been recently proved to be related to altered cell migration and matrix metalloproteinases (MMPs) activity, and reduced angiogenesis in response to VEGF of the endothelial cells (15) . From the viewpoint of (3, 7, 11, 21, 22, 24) . The genetic analysis of Cav-1 showed that the altered expression levels of Cav-1 in different cancer cell lines may not be caused by spontaneous mutations on Cav-1 gene (5, 7). All these findings raised our curiosity that whether the personal susceptibility to RCC was determined at upstream of the molecular biology central dogma, the DNA level via inherited polymorphic genotypes. In this study, up to six SNPs of Cav-1, C521A (rs1997623), G14713A (rs3807987), G21985A (rs12672038), T28608A (rs3757733), T29107A (rs7804372), and G32124A (rs3807992), were genotyped and analyzed of their distributions among the 92 RCC patients and 580 non-cancer healthy subjects in Taiwan. The results showed that individual genotypes of Cav-1 G14713A and T29107A were associated with the susceptibility of RCC (Table 2) , while the genotypes of other four Cav-1 SNPs were not. In addition, the haplotypic analysis about Cav-1 G14713A and T29107A showed that compared with G14713A/ T29107A wild-type GG/TT haplotype, those subjects with "GG/AT or GG/AA" haplotypes were of higher RCC risk, while those with other haplotypes, including AG/TT, "AG/AT or AG/AA", "AA/TT, AA/AT or AA/AA", were of similar level of odds ratio to those of wild-type GG/TT haplotype ( Table 4 ). The haplotype analysis also supported the findings in allelic frequency analysis that A allele of G14713A was protective, and A allele of T29107A was risky for RCC susceptibility ( Table 3 ). The similar trends of significance in the "GG/AT or GG/AA" subgroup after ageand behavior-adjustments strengthen the accuracy and reliability of our findings, also, the frequencies of Cav-1 polymorphisms variant alleles were similar to those reported in the NCBI website in other Asian population studies. Take the minor A allele frequency of Cav-1 G14713A for instance, the proportion is 22.6% in our control group which is very close to the proportions of 16.7% for Beijing and 22.2% for Tokyo populations in NCBI.
We are also interested in the interaction of Cav-1 genotypes and life-style factors on RCC risk. However, it was found that neither the Cav-1 G14713A AA genotype nor the Cav-1 T29107A TT genotype has significant interaction with smoking, alcohol drinking, or hypertension, diabetes or family cancer history on RCC risk (data not shown). The sample size may be a limitation of this study and further validation of our findings with enlarged case sample and functional phynotypic studies are needed.
In conclusion, this is the first report to provide evidence for Cav-1 G14713A and T29107A, but not C521A, G21985A, T28608A, or G32124A, were associated with higher RCC risk. People with GG/AT or GG/AA haplotype at Cav-1 G14713A/T29107A were specifically of elevated risk to RCC, and were suggested to adapt and take better care of their personal behavior and diet in their daily life.
